📚 Wiki Weight Loss & Metabolic Adipotide

Adipotide

● Preclinical / NCI-funded
Adipotide (FTPP, Fat-Targeting Proapoptotic Peptide)
Also known as: FTPP, CKGGRAKDC-GG-D(KLAKLAK)2, Prohibitin-targeting peptide
Page last reviewed

Quick Summary

Adipotide (FTPP) is an experimental peptidomimetic that selectively targets and destroys blood vessels supplying white adipose tissue. It consists of a homing peptide that binds prohibitin on adipose vasculature, linked to a proapoptotic sequence that triggers cell death in the targeted vessels.

Metabolic & Mitochondrial Preclinical
Adipotide (FTPP) is an experimental peptidomimetic that selectively targets and destroys blood vessels supplying white adipose tissue. It consists of a homing peptide that binds prohibitin on adipose vasculature, linked to a proapoptotic sequence that triggers cell death in the targeted vessels. As the blood supply is eliminated, adipocytes starve and die. Primate studies showed dramatic fat loss with preservation of lean mass, but significant nephrotoxicity was observed at research doses.
Storage Stability
Lyophilized
6–12 months (2–8°C)
Reconstituted
~30 days (2–8°C)
Room temp
Avoid

Mechanism of Action

Adipotide is a bipartite peptide with two functional domains joined by a GG linker.

Homing Domain: CKGGRAKDC

This sequence binds prohibitin, a protein highly expressed on the luminal surface of blood vessels feeding white adipose tissue. Prohibitin serves as the address label that delivers the peptide specifically to fat vasculature.

Apoptotic Domain: D(KLAKLAK)2

Once homed to adipose vasculature, the D(KLAKLAK)2 sequence inserts into mitochondrial membranes of vascular endothelial cells, disrupting membrane potential and triggering apoptosis.

Selective Fat Loss

As adipose vasculature is destroyed, the surrounding fat cells lose blood supply and undergo ischemic apoptosis. Lean tissue vasculature does not express prohibitin at the same density, providing selectivity.

Research Summary

Primate Study (2011)

The landmark NCI-funded study in obese rhesus monkeys showed 39% reduction in visceral fat and 27% reduction in subcutaneous fat over 28 days at 1 mg/kg/day. BMI dropped significantly. Lean mass was preserved.

Nephrotoxicity

All animals showed kidney damage at the research dose, with elevated creatinine and BUN. Kidney function recovered partially after cessation, but this is the primary barrier to clinical development.

Dose-Finding

No dose has been identified that separates fat loss efficacy from renal toxicity. This remains an active research problem.

Calculate your Adipotide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →

Research Protocols

Note: Adipotide carries significant nephrotoxicity risk at doses that produce fat loss in primates. Kidney function monitoring (creatinine, BUN) is essential in any research context.

Research Dose

NCI primate protocols used 1 mg/kg subcutaneously daily for 28 days. Lower doses (0.1–0.5 mg/kg) have been explored but efficacy data is limited.

Hydration

High fluid intake is critical during research protocols to reduce renal stress.

Storage & Handling

Store lyophilized" class="wiki-gloss-link">lyophilized powder at -20°C. Reconstitute with sterile water. Use reconstituted solution within 7 days when stored at 2–8°C. Protect from freeze-thaw cycles after reconstitution.


References

  • [1]Barnhart KF, et al. "A peptidomimetic targeting white fat causes weight loss." Science Translational Medicine, 2011.
  • [2]Kolonin MG, et al. "Reversal of obesity by targeted ablation of adipose tissue." Nature Medicine, 2004.
Ready to dose Adipotide?
Get the exact syringe draw
You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.
Open the Calculator →
Verified Scientific Data Last audited:
Data Sources & External References
Source: peer-reviewed literature  ·  Domain: ascendpeptide.org
Adipotide
Peptide calculator, vial + dose → draw volume
Dose Adipotide →

Suggest a Change

Adipotide · wiki page